Business Combinations - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jul. 16, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 01, 2022	Dec. 31, 2021
Business Combinations and Disposals [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001		$ 0.0001			$ 0.0001
Conversion of common stock term				At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:   a) each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $0.0001 per share (the “Class A Common Stock” or “Common Stock”) equal to the Exchange Ratio (as defined below) (the “Per Share Merger Consideration”);   b) each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, “Legacy Celularity Capital Stock”) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto;   c) each share of First Merger Sub common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of the Surviving Corporation;   d) each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Class A Common Stock (and not Celularity Capital Stock) (each, a “Converted Warrant”) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the “Celularity Warrant Shares”) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below); and (B) the per share exercise price for each share of Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below); and   e) each option to purchase Legacy Celularity Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a “Legacy Celularity Option”) was assumed by GX and converted into an option to purchase shares of Class A Common Stock (each, a “Converted Option”).
Goodwill		$ 123,304,000		$ 123,304,000			$ 123,304,000
Business acquisition transaction costs proceeds, net	$ 108,786,000
Business acquisition, transaction costs	$ 21,658,000
Liabilities		279,187,000		279,187,000			$ 314,710,000
Expense reduction in fair value of warrants		$ (43,212,000)	$ 1,174,000	$ (22,280,000)	$ 37,679,000
Common stock, shares issued		142,384,167		142,384,167			124,307,884
Common stock, shares outstanding		142,384,167		142,384,167			124,307,884
Subscription Agreements, description				On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc. (“Sorrento”), Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the “Subscribers”) purchased from Celularity an aggregate of 8,340,000 shares of Class A Common Stock (the “July 2021 PIPE Shares”), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the “Subscription Agreements”). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the July 2021 PIPE Shares.
Aggregate purchase price				$ 30,000,000
GX Warrants
Business Combinations and Disposals [Line Items]
Warrant or Right, Reason for Issuance, Description				In addition, GX had previously issued public warrants and private placement warrants (collectively, the “GX Warrants”) as part of the Units in its IPO in May 2019
Liabilities		$ 59,202,000		$ 59,202,000
Fair value of warrants				23,427,000
Expense reduction in fair value of warrants		$ 30,482,000		$ 9,550,000
First Merger Sub
Business Combinations and Disposals [Line Items]
Common stock, par value (in Dollars per share)	$ 0.01
Surviving Corporation
Business Combinations and Disposals [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001
GX Trust Account
Business Combinations and Disposals [Line Items]
Business acquisition transaction costs proceeds, net	$ 5,386,000
Public Equity Financing
Business Combinations and Disposals [Line Items]
Business acquisition transaction costs proceeds, net	$ 83,400,000
Public Equity Financing | Private Placement
Business Combinations and Disposals [Line Items]
Purchase price	$ 10.00
Palantir Technologies, Inc
Business Combinations and Disposals [Line Items]
Business acquisition transaction costs proceeds, net	$ 20,000,000
Purchase price	$ 10.00
Aggregate number of shares purchased	2,000,000
Aggregate purchase price	$ 20,000,000
Legacy Celularity
Business Combinations and Disposals [Line Items]
Equity classification of Legacy Celularity warrants	$ 96,398,000
Warrants outstanding to purchase shares of common stock						13,281,386
Class A Common Stock
Business Combinations and Disposals [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001		$ 0.0001
Goodwill	$ 0
Other intangible assets	0
Business acquisition, transaction costs relating to merger by issuance of common stock offset against additional paid-in capital	$ 10,795,000
Class A Common Stock | Celularity
Business Combinations and Disposals [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001
Each one Shares reflecting as exchange ratio in business combination	$ 0.7686
Common stock, shares issued	122,487,174
Common stock, shares outstanding	122,487,174
Option to purchase shares of common stock	21,723,273
Warrants outstanding to purchase shares of common stock	42,686,195
Class A Common Stock | Public Equity Financing | Private Placement
Business Combinations and Disposals [Line Items]
Aggregate number of shares purchased	8,340,000
Aggregate purchase price	$ 83,400,000